← boardnext 2029-01
JBIO
Jade Biosciences, Inc.distress 6/10 · elevated risk$19.35-3%today-28% from 52w high
Lead: rheumatoid arthritis · est. market ~$25B (approx, global)
Revenue
pre-revenue
Liquidity
$311M
Runway
3.1 yrs
Shares 1y
+51%
Price & events
+13.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.5%
1D
-5.5%
1W
-11.9%
1M
-23.2%
3M
+18.7%
6M
+122.2%
1Y
-68.4%
2Y
-96.0%
5Y
-97.5%
All
Overview
- Market Cap
- $955.11M
- Volume
- 11.29K
- 52 Week Range
- $6.77 – $26.85
- Total Shares
- 49.36M
- Float Shares
- 37.11M
- Short %
- 16.55%
- % Held by Insiders
- 0.83%
- % Held by Institutions
- 88.14%
- RVOL
- 0.01x
Pipeline stages · 1 programs
JADE101
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2029-01 Estimated 50% readout ~2029-02-15 | Phase 2 | JADE101 | IgA Nephropathy | — | recruiting |
Catalyst news & presentations · 14
- 2027Guided 40%readoutPhase 2JADE101 · Interim data from Phase 2 JUNIPER trial anticipatedSEC 8-K
- 2027Guided 40%readoutPhase 1JADE201 · interim data anticipatedSEC 8-K
- first half of 2027Guided 55%trial initiationsecondaryPhase 1JADE301 · Phase 1 clinical trial expected to commenceSEC 8-K
- 1H27Guided 55%trial initiationsecondaryPhase 1JADE-003 · First-in-human trial initiation.SEC 8-K
- first half of 2027Guided 55%trial initiationsecondaryPhase 3JADE101 · Registrational Phase 3 trial plannedSEC 8-K
- 2026-08-13earningsEarningsEarnings releaseyahoo
- first half of 2026readoutPhase 1JADE101 · Interim biomarker-rich data from Phase 1 healthy volunteer study to define dose and dosing interval for Phase 2 and Phase 3 trials.SEC 8-K
- 1H26trial initiationsecondaryPhase 1JADE-002 · First-in-human trial initiation.SEC 8-K
- second quarter of 2026trial initiationsecondaryPhase 1JADE201 · first-in-human study in rheumatoid arthritis patientsSEC 8-K
- mid-2026trial initiationsecondaryPhase 2JADE101 · Phase 2 clinical trial expected to beginSEC 8-K
- 1H26readoutPhase 1JADE-001 · Interim data from healthy volunteer trial expected.SEC 8-K
- January 15, 2026conferencedata presentationsecondaryCompany to present at 44th Annual J.P. Morgan Healthcare ConferenceSEC 8-K
- 2H25trial initiationsecondaryPhase 1JADE-001 · First-in-human trial initiation for anti-APRIL mAb in IgAN.SEC 8-K
- 2025-10-03partnershipJADE201 (anti-BAFF-R) · Exclusive worldwide license from Paragon Therapeutics for development and commercializationSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $49 (+151% upside) · 8 analysts
- 2026-06-15UBSBuy
- 2026-06-02WedbushOutperform
- 2026-06-01BTIGBuy
- 2026-06-01HC Wainwright & Co.Buy
- 2026-05-27BTIGBuy
- 2026-05-11GuggenheimBuy
Competitors — rheumatoid arthritis
- ABBVAbbVie Inc.$451.1B · D2
- NVSEFNOVARTIS AG$292.0B · D3
- AMGNAMGEN INC$195.4B · D3
- ROIVRoivant Sciences Ltd.$25.1B · D0
- SYRESpyre Therapeutics, Inc.$8.5B · D6
- AVLNAvalyn Pharma Inc.$1.3B · D4
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- ARTVArtiva Biotherapeutics, Inc.$231M · D2
- NKTXNkarta, Inc.$166M · D3
- XBITXBiotech Inc.$69M · D1
Recent news
- 2026-07-19Jade Biosciences Company Profile & Introduction - Moomoo
- 2026-07-17Paradigm funds disclose significant Jade Biosciences (JBIO) ownership in Schedule 13G - Stock Titan
- 2026-07-09Price to sales forward of Jade Biosciences, Inc. – NASDAQ:JBIO - TradingView
- 2026-07-08Enterprise value to EBIT forward of Jade Biosciences, Inc. – NASDAQ:JBIO - TradingView
- 2026-07-08Janus Henderson holds 6.27M JBIO shares, reporting 10.6% stake (JBIO) - Stock Titan
- 2026-07-03Jade Biosciences (JBIO) Joins Growth Indexes, Is The Stock Still Undervalued? - Sahm
- 2026-07-01JBIO - Jade Biosciences Inc Latest SEC Filings - Finviz
- 2026-06-30Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market? - Yahoo Finance
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.